Where the math is defensible.
Long-form research on live enterprise decisions. Publication is selective. Every number traces to a named source. No takes without evidence.
GLP-1 Global Supply Chain 2026: From Shortage to Surplus, From Pricing Power to Pushback
Semaglutide and tirzepatide are exiting the FDA shortage list, compounding pharmacies are losing legal cover, and Indian generics are rewriting the affordability curve. The next bottleneck is payer authorization, not vials.
GLP-1 receptor agonists have moved from a manufacturing crisis into a payer crisis in 18 months. Novo Nordisk and Eli Lilly together invested more than 60 billion dollars in capacity through 2024 and 2025, the FDA removed semaglutide and tirzepatide from the formal shortage list in early 2025, and the 503A and 503B compounding gray market...
Trump pharma tariffs and the US drug supply chain through 2026: Section 232, Ireland exposure, and the API reshoring arithmetic
The April 2025 Section 232 pharmaceuticals investigation, the Ireland headline import number, and the India and China API base together define the 2026 corridor. We map the import stack, the announced reshoring capex, the IRA Year 2 negotiation list, and the 2026 to 2028 buyer playbook.
The Trump administration commenced a Section 232 pharmaceuticals investigation on April 1, 2025 under the Bureau of Industry and Security (BIS) at the Department of Commerce, with public threats of duties between 25 and 200 percent on imported finished drugs and active pharmaceutical ingredients (APIs). United States imports under Harmoni...